SOURCE: Medivation, Inc.

Medivation, Inc.

September 06, 2011 07:01 ET

Medivation Announces Participation at Two Upcoming Investor Conferences

SAN FRANCISCO, CA--(Marketwire - Sep 6, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will participate at the following two investor conferences:

  • Panel discussion titled "Finally Lots of Options in Treating Prostate Cancer" at Citi's 6th Annual Biotech Day on Wednesday, September 7 at 11 a.m. Eastern Time at the Ritz Carlton Boston Commons in Boston, MA

  • Company overview at the UBS Global Life Sciences Conference on Wednesday, September 21 at 10 a.m. Eastern Time at the Grand Hyatt Hotel in New York, NY

A live audio webcast of the company overview will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at

Contact Information

  • Contacts:
    Patrick Machado
    Chief Business & Financial Officer
    (415) 829-4101

    Anne Bowdidge
    Investor Relations
    (650) 218-6900